1st FDA-approved weight-loss drug 'not a miracle cure for obesity, ' says expert

Image
ANI Washington
Last Updated : Jun 10 2013 | 3:35 PM IST

A new long-term weight-loss medication called Beliviq, which had been approved by FDA, will be available to patients by next week.

The drug, which received FDA approval almost a year ago, makes users feel that they are full by working on serotonin transmitters in the brain, which causes this reaction.

CBS News medical contributor Dr. Holly Phillips said on 'CBS This Morning: Saturday' that when a person feels full, they eat less, and then they see the weight loss.

She said that Beliviq was considered to be effective, and people taking it lost around 3.7 percent of their body weight over the year, asserting that in studies the drug worked better in non-diabetics than people who already were diagnosed with that disease.

She said that the drug is not a miracle cure for obesity, but people have to look at it from a health perspective, where if an obese person loses 5 percent of their body weight it can truly benefit you.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 10 2013 | 3:13 PM IST

Next Story